home / stock / kaltf / kaltf news

KALTF News and Press, Kalytera Therapeutics From 03/04/21

Stock Information
Company Name: Kalytera Therapeutics
Stock Symbol: KALTF
Market: OTC
Website: kalytera.co
Menu
KALTF KALTF Quote KALTF Short KALTF News KALTF Articles KALTF Message Board
Get KALTF Alerts

News, Short Squeeze, Breakout and More Instantly...
KALTF - Claritas (formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of COVID-19 with Prophylactic R-107 Nasal Spray Designed to Provide Sustained Release of Nitric Oxide in the Nasal Cavities

SAN FRANCISCO and TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has initiated a second development program with R-107, the ...
KALTF - Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO and TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into a Strategic Collaboration Agreement (the C...

KALTF - Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indi

SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that compelling data demonstrating that nitric oxide achieved viral clearance i...

KALTF - Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO and TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Company will focus its resources primarily on de...
KALTF - Kalytera Announces Resumption of Trading on TSXV

SAN FRANCISCO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that its shares will resume trading today on the TSX VENTURE EXCHANGE (“TSXV”). The Company a...

KALTF - Kalytera Announces Change of Auditor

SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announced today that Kost Forer Gabbay & Kasierer/Ernst & Young Global (“E&Y”) have, at the request of the Company, resi...

KALTF - Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update

SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today provided the following updates regarding recent and ongoing activities. Private Placement As previously announced on July 24, 2020,...
KALTF - Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announced today that on and effective July 22, 2020 it has closed in escrow its previously announced non-brokered private placement (the “...

KALTF - Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection

SAN FRANCISCO, July 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that it has entered into a License Agreement (the “License Agreement” ) with Salzman Group, Inc. ( “Salzman ...

KALTF - Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announces that it has received conditional approval from the TSX Venture Exchange ( " TSXV ”) and partial revocation orders from the Briti...
Previous 10 Next 10